Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center DOI Open Access

C. J. Nicholas,

Andrea Beharry,

Anna Bendzsak

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(14), P. 2505 - 2505

Published: July 10, 2024

Liquid biopsy is rapidly becoming an indispensable tool in the oncologist's arsenal; however, this technique remains elusive a publicly funded healthcare system, and real-world evidence needed to demonstrate utility feasibility. Here, we describe first experience of in-house point care liquid program at Canadian community hospital. A retrospective review consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. initiated discretion clinicians. Sequencing followed workflow using Genexus™ integrated sequencer Oncomine precision assay, performed by histotechnologists. Results were reported attending pathologist. Eligible charts reviewed for outcomes interest, including intent biopsy, results turnaround time from blood draw available. total 124 cases, with confirmed or suspected cancer, between January 2021 November 2023. The median 3 business days (range 1-12 days). sensitivity biopsies 71%, compared tissue testing matched available comparison. Common mutations included

Language: Английский

Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center DOI Open Access

C. J. Nicholas,

Andrea Beharry,

Anna Bendzsak

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(14), P. 2505 - 2505

Published: July 10, 2024

Liquid biopsy is rapidly becoming an indispensable tool in the oncologist's arsenal; however, this technique remains elusive a publicly funded healthcare system, and real-world evidence needed to demonstrate utility feasibility. Here, we describe first experience of in-house point care liquid program at Canadian community hospital. A retrospective review consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. initiated discretion clinicians. Sequencing followed workflow using Genexus™ integrated sequencer Oncomine precision assay, performed by histotechnologists. Results were reported attending pathologist. Eligible charts reviewed for outcomes interest, including intent biopsy, results turnaround time from blood draw available. total 124 cases, with confirmed or suspected cancer, between January 2021 November 2023. The median 3 business days (range 1-12 days). sensitivity biopsies 71%, compared tissue testing matched available comparison. Common mutations included

Language: Английский

Citations

5